 BridgeBio Pharma, Inc. NASDAQ:BBIO, a clinical-stage biopharmaceutical company focused on genetic diseases, announced today that it was unable to come to an agreement with the Special Committee formed by its subsidiary Eidos Therapeutics EIDX, a clinical-stage biopharmaceutical company developing AG10 for the treatment of transthyretin amyloidosis ATTR, to acquire the outstanding common stock of Eidos that BridgeBio does not already own approximately 34 of Eidoss outstanding shares. Subsequent to an initial offer of 1.3 BridgeBio shares for each Eidos share, the offer was raised twice, resulting in a final offer equivalent to 1.5 BridgeBio shares for each Eidos share with an option for Eidos shareholders to receive a portion of that consideration in cash. 